The authors suggested that these genes may influence the regional pattern of volume loss and, thus, the disease phenotype; for instance, patients with MAPT and CXCR4 susceptibility variants may have a higher risk of developing PSP, while patients with MAPT, MOBP, and GLDC may be at greater risk for CBD/CBS or FTD than PSP. The gene discussed is CXCR4; the disease is supranuclear palsy, progressive, 1.